Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 26 clinical trials
A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

, aldesleukin, and pembrolizumab (if assigned) Participants will stay in the hospital for treatment. This includes: Daily chemotherapy for 1 week For some participants, pembrolizumab

hepatitis b antigen
preparative regimen
platelet count
fludarabine
melanoma skin
  • 21 views
  • 16 Jun, 2022
  • 1 location
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

different doses of KK-LC-1 TCR T cells plus aldesleukin to treat metastatic or refractory/recurrent KK-LC-1 positive cancers. Eligibility Adults aged 18 and older with

  • 0 views
  • 27 Jun, 2022
  • 1 location
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

from the patient.} Treatment: Once their cells have grown, the patients will be admitted to the hospital for the conditioning chemotherapy, the TIL cells and aldesleukin. They will stay in the

cyclophosphamide
x-rays
glioblastoma
platelet count
fludarabine
  • 39 views
  • 20 Jun, 2022
  • 1 location
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

grown, the patients will be admitted to the hospital for the conditioning chemotherapy, the TIL cells and aldesleukin. They will stay in the hospital for about 4 weeks for the treatment.

adenosquamous carcinoma
x-rays
alt/ast
platelet count
squamous cell carcinoma
  • 34 views
  • 29 Jun, 2022
  • 1 location
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

Background In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. This is called gene transfer. For this …

immunohistochemistry
hepatitis b antigen
antibiotics
platelet count
white blood cell count
  • 70 views
  • 17 Jun, 2022
  • 1 location
E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Background Human papillomavirus (HPV) can cause cervical, throat, anal, and genital cancers. Cancers caused by HPV have a HPV protein called E7 inside of their cells. In this new therapy, researchers take a person s blood, remove certain white blood cells, and insert genes that make them to target cancer …

hepatitis b antigen
platelet count
cancer
neutrophil count
chemotherapy drugs
  • 370 views
  • 28 Jun, 2022
  • 1 location
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Background A new cancer therapy involves taking white blood cells from a person, growing them in the lab, genetically modifying them, then giving them back to the person. This therapy is called gene transfer using anti-KRAS G12V mTCR cells. Objective To see if anti-KRAS G12 V mTCR cells are safe …

hepatitis b antigen
antibiotics
platelet count
fludarabine
cancer
  • 31 views
  • 27 Jun, 2022
  • 1 location
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Background A new cancer therapy takes white blood cells from a person, grows them in a lab, genetically changes them, then gives them back to the person. Researchers think this may help attack tumors in people with certain cancers. It is called gene transfer using anti-KRAS G12D mTCR cells. Objective …

hepatitis b antigen
antibiotics
platelet count
fludarabine
cancer
  • 14 views
  • 29 Jun, 2022
  • 1 location
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

This phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) or LN-145-S1 works in treating patients with ovarian cancer, anaplastic thyroid cancer, osteosarcoma, or other bone and soft tissue sarcomas that do not respond to treatment (refractory) or that has come back (relapsed). LN-145 is made by …

ifosfamide
platelet count
cancer
neutrophil count
measurable disease
  • 325 views
  • 27 Feb, 2022
  • 1 location
Low-dose Interleukin-2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes - IVORY (IVORY)

Acute coronary syndromes (ACS) result from coronary plaque(s) disruption, which initiates a thrombotic process leading to partial or complete obstruction of the vessel lumen with subsequent myocardial ischaemia and necrosis. The mainstay of treatment is currently focused on the re-establishment and maintenance of coronary artery patency using anti-platelets and anticoagulants …

  • 0 views
  • 13 Jun, 2022
  • 1 location